NO20005883D0 - Anvendelse av <alfa>-1-<beta>-integrin-reseptorinhibitorer og TGF-<beta>-1-inhibitorer i behandling av nyresykdom - Google Patents

Anvendelse av <alfa>-1-<beta>-integrin-reseptorinhibitorer og TGF-<beta>-1-inhibitorer i behandling av nyresykdom

Info

Publication number
NO20005883D0
NO20005883D0 NO20005883A NO20005883A NO20005883D0 NO 20005883 D0 NO20005883 D0 NO 20005883D0 NO 20005883 A NO20005883 A NO 20005883A NO 20005883 A NO20005883 A NO 20005883A NO 20005883 D0 NO20005883 D0 NO 20005883D0
Authority
NO
Norway
Prior art keywords
beta
alpha
inhibitors
integrin receptor
tgf
Prior art date
Application number
NO20005883A
Other languages
English (en)
Other versions
NO20005883L (no
Inventor
Dominic Gosgrove
Original Assignee
Boys Town Nat Res Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boys Town Nat Res Hospital filed Critical Boys Town Nat Res Hospital
Publication of NO20005883D0 publication Critical patent/NO20005883D0/no
Publication of NO20005883L publication Critical patent/NO20005883L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K3/00—Materials not provided for elsewhere
    • C09K3/18—Materials not provided for elsewhere for application to surfaces to minimize adherence of ice, mist or water thereto; Thawing or antifreeze materials for application to surfaces
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Combustion & Propulsion (AREA)
  • Materials Engineering (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO20005883A 1998-05-22 2000-11-21 Anvendelse av <alfa>1<beta>1-integrinreseptorinhibitorer og TGF-<beta>1-inhibitorer i behandling av nyresykdom NO20005883L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US8658798P 1998-05-22 1998-05-22
US8876698A 1998-06-02 1998-06-02
US15048598A 1998-09-09 1998-09-09
PCT/US1999/011073 WO1999061040A2 (en) 1998-05-22 1999-05-19 USE OF α1β1 INTEGRIN RECEPTOR INHIBITORS AND TGF-β1 INHIBITORS IN THE TREATMENT OF KIDNEY DISEASE

Publications (2)

Publication Number Publication Date
NO20005883D0 true NO20005883D0 (no) 2000-11-21
NO20005883L NO20005883L (no) 2001-01-17

Family

ID=56289911

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20005883A NO20005883L (no) 1998-05-22 2000-11-21 Anvendelse av <alfa>1<beta>1-integrinreseptorinhibitorer og TGF-<beta>1-inhibitorer i behandling av nyresykdom

Country Status (21)

Country Link
EP (1) EP1079843B1 (no)
JP (1) JP2002516287A (no)
CN (1) CN1187084C (no)
AT (1) ATE359804T1 (no)
BR (1) BR9911067A (no)
CA (1) CA2329757C (no)
CZ (1) CZ296262B6 (no)
DE (1) DE69935853T2 (no)
DK (1) DK1079843T3 (no)
EA (1) EA004145B1 (no)
EE (1) EE04581B1 (no)
ES (1) ES2285841T3 (no)
HU (1) HUP0202048A3 (no)
NO (1) NO20005883L (no)
NZ (1) NZ508317A (no)
PL (1) PL345946A1 (no)
PT (1) PT1079843E (no)
SG (1) SG117434A1 (no)
SI (1) SI1079843T1 (no)
TR (1) TR200003432T2 (no)
WO (1) WO1999061040A2 (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1488806B1 (en) 1999-06-01 2015-12-09 Biogen MA Inc. A blocking monoclonal antibody to VLA-1 and its use for the treatment of vascular disorders
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
PT1214091E (pt) * 1999-09-14 2006-09-29 Imperial College Terapias para a insuficiencia renal cronica utilizando um ou mais antaginistas de integrina
CA2400628A1 (en) * 2000-03-09 2001-09-13 Genzyme Corporation Use of tgf-beta antagonists to treat or to prevent loss of renal function
ES2347532T3 (es) 2001-04-13 2010-11-02 Biogen Idec Ma Inc. Anticuerpos contra vla-1.
EA200500576A1 (ru) 2002-11-01 2006-02-24 Бойз Таун Нэшнл Рисерч Хоспитал ИНДУЦИБЕЛЬНЫЙ ЛИГАНД ИНТЕГРИНА α1β1 И ПРИМЕНЕНИЯ
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
ES2685802T3 (es) 2006-05-25 2018-10-11 Biogen Ma Inc. Antagonista de VLA-1 para su utilización en el tratamiento de un accidente cerebrovascular
GB0911888D0 (en) * 2009-07-08 2009-08-19 Oxford Biodynamics Ltd Method of treating age related disorders
CN113249381A (zh) 2011-04-25 2021-08-13 赛诺菲 用于调节mir-21活性的微rna化合物以及方法
US10316095B2 (en) 2012-02-16 2019-06-11 Santarus, Inc. Antibody formulations
KR20230037703A (ko) 2012-04-25 2023-03-16 사노피 마이크로rna 화합물 및 mir-21 활성 조절 방법
UA116639C2 (uk) * 2012-10-09 2018-04-25 Рег'Юлес Терап'Ютікс Інк. Способи лікування синдрому альпорта
CN104450726A (zh) * 2013-09-17 2015-03-25 深圳华大基因科技有限公司 Col4a5基因突变体及其应用
CN104212806B (zh) * 2014-07-21 2017-05-17 深圳华大基因股份有限公司 Alport综合征新的突变致病基因及其编码蛋白和应用
US20230374141A1 (en) * 2020-10-05 2023-11-23 Father Flanagan's Boys' Home Doing Business As Boys Town National Research Hospital Combination therapy for alport renal disease
CN112575074B (zh) * 2020-10-09 2022-12-27 中山大学 Nestin基因及蛋白在治疗器官纤维化中的应用
WO2023085396A1 (ja) * 2021-11-12 2023-05-19 Ｕｂｅ株式会社 アルポート症候群を治療または予防するための医薬組成物
CN114698592B (zh) * 2022-04-29 2022-11-04 中国医学科学院北京协和医院 一种干燥综合征肾损害小鼠模型的构建方法及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9519667D0 (en) * 1995-09-27 1995-11-29 Univ Manchester Pharmaceutical composition

Also Published As

Publication number Publication date
EA004145B1 (ru) 2004-02-26
CN1187084C (zh) 2005-02-02
PL345946A1 (en) 2002-01-14
DE69935853D1 (de) 2007-05-31
EP1079843B1 (en) 2007-04-18
EA200001092A1 (ru) 2001-06-25
CZ296262B6 (cs) 2006-02-15
WO1999061040A9 (en) 2001-02-01
BR9911067A (pt) 2001-02-06
TR200003432T2 (tr) 2001-03-21
HUP0202048A2 (en) 2002-10-28
CA2329757A1 (en) 1999-12-02
CZ20004358A3 (cs) 2002-01-16
NO20005883L (no) 2001-01-17
HUP0202048A3 (en) 2006-11-28
DK1079843T3 (da) 2007-07-30
SI1079843T1 (sl) 2007-10-31
EE04581B1 (et) 2006-02-15
CA2329757C (en) 2013-11-19
NZ508317A (en) 2004-01-30
WO1999061040A3 (en) 2000-01-27
EP1079843A2 (en) 2001-03-07
EE200000685A (et) 2002-04-15
WO1999061040A2 (en) 1999-12-02
PT1079843E (pt) 2007-06-26
JP2002516287A (ja) 2002-06-04
CN1310625A (zh) 2001-08-29
SG117434A1 (en) 2005-12-29
DE69935853T2 (de) 2008-01-10
ATE359804T1 (de) 2007-05-15
ES2285841T3 (es) 2007-11-16

Similar Documents

Publication Publication Date Title
NO20005883D0 (no) Anvendelse av &lt;alfa&gt;-1-&lt;beta&gt;-integrin-reseptorinhibitorer og TGF-&lt;beta&gt;-1-inhibitorer i behandling av nyresykdom
BR0107565A (pt) Formas de dosagem de benzimidazol substituìdo e método de emprego das mesmas
AU5338301A (en) Methods and compositions for modulating alpha adrenergic receptor activity
MY135732A (en) 5,6-trimethylenepyrimidin - 4 - one compounds
DE60023043T2 (de) (S,S)-Reboxetin zur Behandlung von Inkontinenz
TR200001312T2 (tr) Benzotiyazol protein tirozin kinaz önleyicileri.
NZ516562A (en) Pyrimidine-2,4,6-trione metalloproteinase inhibitors
TR200000756T2 (tr) Davranış bozukluğu tedavisi.
HUP0104688A2 (hu) Összetételek és eljárások a rákbetegség és a rákbetegséggel kapcsolódó csontveszteség megelőzéséhez és kezeléséhez
BG105112A (bg) Средство с антидепресивно действие
BR0309095A (pt) Uso de osteoprotegerina para o tratamento e/ou prevenção de doença fibrótica
AU5338401A (en) Methods and compositions for modulating alpha adrenergic receptor activity
ATE333896T1 (de) Vaskularisierungsinhibitoren
ES2216630T3 (es) Metodos de tratar la hipertension dependiente de la sal.
NO994431L (no) Ny formulering
NO980221L (no) Fremgangsmåte for behandling av tykktarmsadenomer
DE60121048D1 (de) PYRAZINOi1&#39;2&#39;:1,6öPYRIDOi3,4-BöINDOLDERIVATE
TR200200278T2 (tr) Kalsilitik bileşimler
YU39598A (sh) Upotreba duloksetina i njegova farmaceutska smeša
DK1152757T3 (da) MMP-inhibitorer i bindevævsblödhed
CY1108053T1 (el) Ενωση της κυαμεμαζινης και ενος ατυπου νευροληπτικου
ATE344662T1 (de) Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
EP1613585A4 (en) COMPOUNDS AND METHOD FOR USE IN THE TREATMENT OF NEOPLASMS AND CANCER BASED ON INHIBITORS OF ISOPRENYLCYSTEIN METHYLTRANSFERASE
ATE353642T1 (de) Verwendung von hypoestoxiden als antiparasitäre mittel
NO20030985D0 (no) Behandling av betennelsestilstander

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application